Katherine Edwards

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 12

Top Venues

PharmacoEconomics - open

Health technology assessment (Winchester, England)

Health economics review

University of Liverpool

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Liverpool Feb 17 2020

United Kingdom

Research Associate

Publications

Nigel Fleeman, Rachel Houten, Sarah Jane Nevitt, James Mahon, Sophie Beale, Angela Boland, Janette Greenhalgh, Katherine Edwards, Michelle Maden, Devarshi Bhattacharyya, Marty Chaplin, Joanne McEntee, Shien Chow, Tom Waddell
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis. Health technology assessment (Winchester, England) 28 (49) (2024)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open 7 (3) (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open 7 (3) (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rebecca Bresnahan, Rui V Duarte, James Mahon, Sophie Beale, Marty Chaplin, Devarshi Bhattacharyya, Rachel Houten, Katherine Edwards, Sarah Jane Nevitt, Michelle Maden, Angela Boland
Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation. Health technology assessment (Winchester, England) 27 (10) (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open 7 (3) (2023)
Beth Fordham, Thavapriya Sugavanam, Katherine Edwards, Karla Hemming, Jeremy Howick, Bethan Copsey, Hopin Lee, Milla Kaidesoja, Shona Kirtley, Sally Hopewell, Roshan das Nair, Robert J Howard, Paul Stallard, Julia Hamer-Hunt, Zafra Cooper, Prof Sarah E Lamb
Cognitive-behavioural therapy for a variety of conditions: an overview of systematic reviews and panoramic meta-analysis. Health technology assessment (Winchester, England) 25 (9) (2021)
Jonathan L Rees, Anjali Shah, Katherine Edwards, Maria T Sanchez-Santos, Danielle E Robinson, Antonella Delmestri, Andrew J Carr, Nigel K Arden, Prof Sarah E Lamb, Amar Rangan, Andrew Judge, Rafael Pinedo-Villanueva, Tim A Holt, Sally Hopewell, Daniel Prieto Alhambra, Gary Stephen Collins
Treatment of first-time traumatic anterior shoulder dislocation: the UK TASH-D cohort study. Health technology assessment (Winchester, England) 23 (18) (2020)
Katherine Edwards, Natasha Jones, Julia Newton, Charlie Foster, Andrew Judge, Kate Jackson, Nigel K Arden, Rafael Pinedo-Villanueva
The cost-effectiveness of exercise-based cardiac rehabilitation: a systematic review of the characteristics and methodological quality of published literature. Health economics review 7 (1) (2017)

Katherine Edwards.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Katherine Edwards